GDTC CytoMed Therapeutics Ltd: institutional ownership and insider trading
3 funds reported holding $12.2K of CytoMed Therapeutics Ltd in their latest 13F filings; in Q2 2026 funds net sold $4.59K, with 1 new positions and 1 funds selling out; over the last 12 months insiders bought $429K and sold $0 on the open market.
Largest institutional holders of GDTC
- Axiom Investment Management LLC — $7.24K
- UBS Group AG (UBS) — $4.98K
- OSAIC HOLDINGS, INC. — $21
Recent GDTC insider trades
- Jul 20, 2026: Choo Chee Kong bought 200,000 shares ($300K)
- May 13, 2026: Choo Chee Kong bought 112,000 shares ($129K)
5%+ owners
- Choo Chee Kong: 25.2% (Schedule 13D/A, filed Oct 16, 2026)
- mDR LTD: 10.0% (Schedule 13G/A, filed Oct 23, 2026)
Who owns the most GDTC stock?
The largest institutional holders of CytoMed Therapeutics Ltd in the latest 13F filings are Axiom Investment Management LLC ($7.24K), UBS Group AG (UBS) ($4.98K), OSAIC HOLDINGS, INC. ($21).
Are insiders buying or selling GDTC?
Over the last 12 months insiders bought $429K and sold $0 of CytoMed Therapeutics Ltd stock on the open market (SEC Form 4).